Evonik

Evonik

Global specialty chemicals manufacturer and supplier

Overview

Evonik is a global specialty chemicals company that makes high-value ingredients used in everyday products, such as cars, footwear, and animal feed. Its products are designed to enhance performance by providing tailored chemical solutions across multiple industries and applications. Evonik operates in more than 100 countries, producing specialty chemicals through advanced formulations and manufacturing processes that meet specific customer needs. The company differentiates itself by its focused strategy on high-margin specialty chemicals after restructuring, its large, multinational manufacturing footprint, and ongoing efficiency-improvement efforts that paused major acquisitions through 2027 to prioritize internal transformation. The goal is to strengthen its leadership in specialty chemicals and sustain profitable growth by delivering specialized ingredients and performance materials while improving operational efficiency.

About Evonik

Simplify's Rating
Why Evonik is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Food & Agriculture

Automotive & Transportation

Industrial & Manufacturing

Consumer Goods

Company Size

10,001+

Company Stage

IPO

Headquarters

Essen, Germany

Founded

2007

Get referred to Evonik

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Evonik raised 2026 EBITDA guidance to €2.0-€2.2 billion on August 4, 2026.
  • Q2 2026 EBITDA hit €630 million, Evonik's strongest quarter in four years.
  • Marl membrane production and Shanghai testing center position Evonik for China's hydrogen buildout.

What critics are saying

  • Evonik will cut 3,200 jobs through 2029, exposing persistent margin pressure.
  • Evonik exits polyester in 2027, signaling stranded assets and weak end-market economics.
  • Singapore methionine force majeure and BASF competition threaten earnings if disruptions persist into 2027.

What makes Evonik unique

  • Evonik's 2026 portfolio centers on specialty chemicals, not commoditized bulk chemicals.
  • DURAION membranes give Evonik a differentiated foothold in green-hydrogen electrolysis.
  • Lafayette's $100 million upgrade deepens Evonik's pharma CDMO manufacturing scale and complexity.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.5B

Above

Industry Average

Funded Over

5 Rounds

Post IPO Convertible funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Convertible Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

Parental Leave

Tuition Reimbursement

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Paid Vacation

Flexible Work Hours

Hybrid Work Options

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

11%
PR Newswire
Jul 8th, 2026
Evonik invests $100M to upgrade Indiana drug substance manufacturing facility

Evonik is investing $100 million over five years to modernise its drug substance manufacturing facility in Lafayette, Indiana. The investment will upgrade equipment including 100 m³ reactors, enhance automation, and improve efficiency at the site. The German chemicals company aims to meet growing demand for US-based contract development and manufacturing organisation services. The Tippecanoe facility is Evonik's second-largest US site and one of the world's largest active pharmaceutical ingredient facilities. The site features 170 m³ of high-potency API capacity, 860 m³ of reactor capacity for general APIs, and 2,500 m³ for large-scale fermentation. Evonik acquired the facility from Eli Lilly in 2010. The modernisation supports production of increasingly complex molecules for cancer, metabolic, and cardiovascular disease treatments whilst reducing greenhouse gas emissions.

AktienSensor
Jun 10th, 2026
Evonik shareholder raises $424M via convertible debt to fund R&D and bolster capital structure

Evonik Industries' principal shareholder, RAG-Stiftung, has issued €375 million in convertible debt maturing in December 2031. The note carries a 1.45% coupon and a conversion price of €19.46 per share, representing a 27% premium over the reference price at issuance. The transaction is part of RAG-Stiftung's long-term capital-raising framework, bringing its total outstanding convertible debt to approximately €1.4 billion. The low coupon reflects disciplined interest expense management in the specialty-chemicals sector. If converted, the debt would retire and dilute the foundation's equity stake by less than 1%. The proceeds will support research and development spending and provide a buffer against commodity price volatility. The German specialty-chemicals company faces competition from BASF, Lanxess and Solvay in high-performance polymers and advanced additives.

Yahoo Finance
Jun 10th, 2026
Evonik launches membrane to cut green hydrogen costs by 25%

German chemicals group Evonik has developed a membrane for electricity-based hydrogen production that could significantly reduce costs. Commercial manufacturing of the Anion Exchange Membrane (AEM) electrolysis system has begun at a pilot plant in Germany's Ruhr region. The technology uses fewer precious metals than traditional methods and allows hydrogen to be produced under pressure, eliminating additional compression steps. Specialist studies suggest the system could reduce investment costs by at least 25%. Green hydrogen currently costs two to four times more than grey hydrogen produced from natural gas. Evonik is targeting large-scale application in China, where it has established a technology centre in Shanghai to test the membranes under industrial conditions with local partners. The company expects strong demand growth for green hydrogen as industries transition to carbon neutrality.

AD HOC NEWS
Jun 3rd, 2026
Evonik shareholders approve $1.4B bond programme and capital increase to fund specialty chemicals shift

Evonik shareholders approved a €1.25 billion convertible bond programme and conditional capital increase of up to 37 million shares at the company's annual general meeting on Tuesday. The measures provide capital for acquisitions as the German chemicals group accelerates its shift toward higher-margin specialty products. The board also proposed a €1.00 per share dividend, totalling roughly €466 million. Deutsche Bank Research maintained its 'Hold' rating with a €16 price target, noting that a sale of Evonik's C4 chemicals unit is expected soon. Evonik shares have climbed 26% year-to-date, trading near €16.85, though technical indicators suggest overbought conditions. The company will report second-quarter results in August.

PR Newswire
May 11th, 2026
Vary Tech, Evonik and SupeZET launch chemical recycling package to turn waste plastics into naphtha

Vary Tech, Evonik and SupeZET have launched a full-chain chemical recycling package at IFAT Munich 2026 that converts waste plastics into high-quality Plastic Pyrolysis Oil and circular naphtha. The technology targets low-value, mixed polyolefin waste that cannot be mechanically recycled. Vary Tech and SupeZET signed a strategic agreement to establish CARBON LOOP SYSTEMS in Singapore, focusing on chemical plastic recycling. The joint venture, alongside Evonik and JE Synergy, will build Asia's first closed-loop chemical recycling demonstration project for post-consumer plastics. The process combines Vary Tech's oxygen-free pyrolysis technology with Evonik's Rocket module and SupeZET's hydrogenation and fractionation systems. Vary Tech's single-unit capacity reaches 150 tonnes daily with over 8,000 annual operating hours, with more than 100 commercial pyrolysis lines delivered globally.

Recently Posted Jobs

Sign up to get curated job recommendations

Evonik is Hiring for 247 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →